Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
AstraZeneca's New Restructuring Initiatives to Drive Productivity and Support Innovation
AstraZeneca Press Release (02/2/12)
In conjunction with the publication of its full year 2011 results, AstraZeneca announced new restructuring initiatives designed to improve productivity and strengthen the company's commercial, operations and research and development capabilities. This new program is expected to deliver an estimated $1.6 billion in annual benefits by the end of 2014, at an estimated total cost of $2.1 billion. AstraZeneca expects that this restructuring program will affect approximately 7,300 positions.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
